Results 51 to 60 of about 1,701 (184)

Analysis of queries in an HIV drug–drug interaction checker to explore changes in prescribing patterns: A 5‐year analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Careful consideration of drug–drug interactions (DDIs) is critical as people with HIV age. We analysed queries submitted to the University of Liverpool HIV Drug Interactions Database to assess changes in prescribing patterns over 5 years. Methods Queries submitted between January 2020 and December 2024 were extracted and categorized by year ...
Cecile Gras, Minh P. Le, Justin Chiong, Sara Gibbons, Daniel Seddon, Catia Marzolini, Saye Khoo   +6 more
wiley   +1 more source

Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial

, 2023
Background: Lenacapavir, a first-in-class HIV-1 capsid inhibitor, is in development as a long-acting agent for treating and preventing HIV-1. We aimed to evaluate the efficacy and safety of lenacapavir with an optimised background regimen in adults ...
David A. Wheeler, Wang H., Joseph P. McGowan, Peter J. Ruane, Segal-Maurer S., Winai Ratanasuwan, William Sanchez, Theo Hodge, Krittaecho Siripassorn, Moti N. Ramgopal, Catherine M. Creticos, Daniel S. Berger, Avihingsanon A., Workowski K., James Sims, Sorana Segal-Maurer, Benoit Trottier, Takuma Shirasaka, Kimberly Workowski, Chien-Ching Hung, Gary Ian Sinclair, Andrea Antinori, Gary J. Richmond, Martin S Rhee, Andrew Wiznia, Gordon E. Crofoot, Hadas Dvory-Sobol, Hui Wang, Dvory-Sobol H., Jean-Michel Molina, Edwin DeJesus, Jason Brunetta, Ratanasuwan W., Molina J. -M., Yazdan Yazdanpanah, Jared M Baeten, Onyema Ogbuagu, Mezgebe Berhe, Brinson C., Ellen Koenig, Hans-Jurgen Stellbrink, Antonella Castagna, Nicolas Margot, Josep Mallolas, Debbie Hagins, Baeten J. M., Yoshiyuki Yokomaku, Cynthia Brinson, Christine Zurawski, Yazdanpanah Y., Ploenchan Chetchotisakd, castelli f., Margot N., Kenneth Lichtenstein, Sylvie Ronot-Bregigeon, Trottier B., Anchalee Avihingsanon, Francesco Castelli, Mohammed Rassool, Antinori A., Rhee M. S., Olayemi Osiyemi, Ogbuagu O.   +62 more
core   +1 more source

Lenacapavir, PrEP demand, and the efficacy-effectiveness gap in South African HIV prevention

South African Medical Journal
South Africa has launched a limited, phased rollout of twice-yearly injectable lenacapavir pre-exposure prophylaxis (PrEP) for HIV prevention. Initially supported by donor funding, the medication is positioned as a turning point in the national HIV ...
W Parker
doaj   +1 more source

ID060 Oportunidades no manejo de indivíduos com vírus da imunodeficiência humana altamente experientes no tratamento

Jornal de Assistência Farmacêutica e Farmacoeconomia
Introdução A supressão virológica figura como um dos principais objetivos do tratamento da síndrome da imunodeficiência humana. Entretanto, pessoas altamente experientes em tratamento com vírus da imunodeficiência humana podem não alcançar a ...
Kelli Carneiro de Freitas Nakata, Helder Cássio de Oliveira   +1 more
doaj   +1 more source

Lenacapavir impurity analysis

Journal of Medicines Development Sciences
On June 20, 2024, Gilead Sciences announced the interim results of the pivotal Phase 3 PURPOSE 1 trial for Lenacapavir, a new HIV prevention drug administered via subcutaneous injection twice a year, demonstrating 100% efficacy in preventing HIV infection in young women.On August 22, 2022, the European Commission approved Lenacapavir globally for use ...
Qingsong Wang, Yongfeng Qiu
openaire   +1 more source

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation

Clinical Pharmacology &Therapeutics, EarlyView.
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary, Robert Bies, Osei Boateng, Rachel Daley, Pierre Gashema, Mili Karina, Emily Njuguna, Sharon Nachman, Nathaniel Nkrumah, Carolyne Odula, Andrew Owen, Ethel D. Weld, Prajith Venkatasubramanian, Adeniyi Olagunju, on behalf of the Community of Practice for Long‐acting Therapeutics for Maternal and Paediatric Health, Rana Abutaima, Dorothy Akongo, Abdulnaser Alsharaa, Moherndran Archary, Shakir Atoyebi, Benoit Bestgen, Robert Bies, Osei Boateng, Andrew Butler, Edmund Capparelli, Rachel Daley, Layla Davies, Joelle Dountio, Henry Enzama, Pierre Gashema, Katila George, Dan Hawcutt, Rene Holm, Patrick Gad Iradukunda, Elodie Jambert, Mili Karina, Linda Lewis, Grace Miheso, Sebastien Morin, Andrew Morrison, Sharon Nachman, Shadia Nakalema, Emily Njunga, Nathaniel Nkrumah, Carolyne Odula‐Obonyo, Brenda Okware, Adeniyi Olagunju, Andrew Owen, Martina Penazzato, Natella Rakhmanina, Mphako Brighton Ratlabyana, Rachel Scott, Kimberly Struble, Andre‐Marie Tchouatieu, Catherine Unsworth, Prajith Venkatasubramanian, Catriona Waitt, Ethel Weld, Janine Winterbottom, Leena Zino   +59 more
wiley   +1 more source

Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access

Clinical Pharmacology &Therapeutics, EarlyView.
Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian, Moherndran Archary, Daniel B. Hawcutt, Rachel Daley, Edmund Capparelli, Adeniyi Olagunju   +5 more
wiley   +1 more source

Novel dolutegravir and lenacapavir resistance patterns in human immunodeficiency virus type 2 infection : a case report [PDF]

Background The treatment management of human immunodeficiency virus (HIV)-2 infection presents greater challenges compared to HIV-1 infection, primarily because of inherent resistance against non-nucleoside reverse transcriptase inhibitors.
van de Vijver, David A M C, Voskamp, Mike, van Kampen, Jeroen J A, Gruters, Rob A; id_orcid, Charpentier, Charlotte, Mahmud, Rizwan, van de Vijver, David A M C; id_orcid, Nijssen, Tess, Krullaars, Zoë, Le Hingrat, Quentin, van Nood, Els, Nijssen, Tessel F., Voskamp, Tess, Gruters, Rob A, Voermans, Jolanda J C, Mesplède, Thibault, Mesplède, Thibault; id_orcid   +16 more
core   +1 more source

Understanding community questions about HIV pre‐exposure prophylaxis (PrEP): A thematic analysis of reddit threads to inform development of an AI chatbot for PrEP education

HIV Medicine, EarlyView.
Abstract Background Despite growing availability of HIV pre‐exposure prophylaxis (PrEP), many potential users turn to online forums for advice and information collection. These forums provide a window into real‐world questions, concerns and misinformation.
Alexandar Vincent‐Paulraj, William Wood, Catia Marzolini, Justin Chiong, Daryl Hodge, Sara Gibbons, Daniel Seddon, Jasmine Martin, Saye Khoo, Lauren E. Waker   +9 more
wiley   +1 more source

Biocatalytic Production of a Key Chiral Intermediate of the HIV Capsid Inhibitor Lenacapavir [PDF]

Lenacapavir is a first-in-class viral capsid inhibitor approved for the treatment of HIV, which has been shown to give almost complete protection against transmission of the virus.
Finnigan, William, Hutton, Amy E., Green, Anthony, Crawshaw, Rebecca, Birmingham, William, Xu, Zefei, Zhao, Fei, Levy, Colin; id_orcid, Rowles, Ian, Turner, Nicholas; id_orcid, Taylor, Christopher, Dunstan, Mark; id_orcid, Ford, Grayson, Ortmayer, Mary   +13 more
core   +1 more source